Medicortex Finland Oyj

Medicortex Finland Oy Announces the Progression of Clinical Trial for Detection of Mild Traumatic Brain Injury in Children

TURKU, Finland. Medicortex Finland Oy announces the progression of clinical trial for detection of mild Traumatic Brain Injury (TBI) and concussion. Company’s third clinical trial is focusing on children and adolescents, and the recruitment of patients is taking place at Satasairaala hospital in Finland. The first patients with head injury and the first healthy controls have been enrolled in the study.

Medicortex Finland Oy tiedottaa lasten ja nuorten tapaturmaisten aivovammojen diagnostiikkaan liittyvän kliinisen tutkimuksen etenemisestä. Yrityksen kolmas kliininen tutkimus toteutetaan Satasairaalassa Porissa. Ensimmäiset päänsä loukanneet potilaat ja terveet verrokit on rekrytoitu tutkimukseen.

“A diagnostic kit for rapid detection of mild TBI in children is important. It will satisfy the pressing need to improve the detection of brain injury in children who suffered a head injury” said Dr. Mårten Kvist, Medical Director of Medicortex Finland Oy. The rapid diagnostic kit ProbTBITM, currently being developed by Medicortex, will help to diagnose brain injury especially in patients who don’t show visible symptoms of brain damage - which is frequently the case with concussion and mild injury.

The clinical trial is conducted at Satasairaala hospital in Pori – the main hospital in Satakunta region with the first level pediatric emergency department and expertise in the TBI management. Body fluid samples are collected from young patients (0 – 17 years) with suspected mild TBI, and the samples will be studied with respect to a specific biomarker signature following a head injury. The Principal Investigator, Dr. Sari Malmi, Head of the Department of Pediatric Surgery, says that a new test for improving the diagnosis of traumatic brain injury is highly needed. It will improve the examination of young patients with a traumatic brain injury and thus improve the quality of their treatment.

"ProbTBITM will be a highly innovative diagnostic kit for rapid detection of concussion. Children in particular will benefit from it since they can be refrained from radiation or sedation which are needed for the CT scan of the head, as well as from an exposure to other sick patients in the hospital" said Dr. Adrian Harel, CEO of Medicortex. “Participation of the young patients shortly after a head injury will be a challenge, but we have a committed and skilled clinical team working with us in the hospital” Dr. Harel adds.

In this clinical trial, Medicortex will collect a sufficient number of pediatric samples in order to prove the applicability of the brain injury test in children, as an expected continuation for previously proven clinical performance in adults. The clinical trial is posted at the public database with identifier NCT04288167.

Medicortex Finland Oy is engaged in the development of first-of-its-kind diagnostic kit for rapid detection of concussion and mild TBI from non-invasive body fluid samples. The Company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. The patent portfolio held by Medicortex secures exclusivity to develop the product. More information about TBI and its detection is available on Company's website at



Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817


About Medicortex Finland Oyj

Medicortex Finland Oyj
Medicortex Finland Oyj
Itäinen Pitkäkatu 4 B
20520 TURKU

Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence and severity of a head injury.

Subscribe to releases from Medicortex Finland Oyj

Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oyj

Medicortex Finland Plc appointing a new advisor1.12.2022 09:30:00 EET | Press release

Medicortex Finland Plc, a biotechnology company located in Turku, Finland, with a proprietary biomarker technology for detection of traumatic brain injury (TBI) and numerous other pipeline product candidates, announced today appointment of Professor Mika Hannula (DSc Tech) as a new member in company’s Scientific and Clinical Advisory Board (SAB). Professor Hannula supplements the team of scientists and clinicians with his diverse expertise in academic research management.

Medicortex Finland Oyj sopimukseen 2 miljoonan dollarin tutkimusrahoituksesta Yhdysvaltain puolustusministeriön kanssa25.10.2022 09:00:00 EEST | Tiedote

Medicortex Finland Oyj, tapaturmaisten aivovammojen diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, tiedottaa, että Yhdysvaltain puolustusministeriö (US Department of Defense, ”DoD”) on myöntänyt yhtiölle noin 2 miljoonan dollarin tutkimusrahoituksen lievän tapaturmaisen aivovamman ja aivotärähdyksen havaitsevan pikatestin kehittämiseen.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom